Cytoprotection, Myocardial Reperfusion Injury
Conditions
Keywords
Myocardial protection, Ischemic Reperfusion Injury, Hyperbaric Oxygen, Preconditioning
Brief summary
The purpose of this study was to determine if treating patients who have coronary heart disease with hyperbaric oxygen (HBO) prior to coronary artery bypass graft (CABG) surgery reduces injury to the heart and vascular system during and after surgery. Furthermore, this study also aims to identify some of the post CABG clinical effects of HBO treatment prior to CABG.
Interventions
DRUGHyperbaric Oxygen
100% Oxygen at 2.4 ATA for 30 minutes followed by 5 minutes break followed by 100% Oxygen at 2.4 ATA for another 30 minutes. This intervention was given about 4 to 5 hours prior to CABG
Sponsors
North of England Medical & Hyperbaric Services
Hull University Teaching Hospitals NHS Trust
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE (Caregiver)
Eligibility
Sex/Gender
ALL
Age
20 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* Patients undergoing elective first time CABG * Patients with at least 1 vessel coronary artery disease undergoing on- pump CABG
Exclusion criteria
* Age ≤ 20 years or ≥ 85 years * Ejection fraction \< 30% * Unstable angina * Recent myocardial infarction (\< 1 month) * Any additional cardiac disease (e.g. arrythmia, aneurysm, valvular/septal disease, dissection or elevated pulmonary artery pressure) * Any end stage organ failure (e.g. renal and respiratory failure) * History of chronic obstructive pulmonary disease (COPD) * Pneumothorax * Pulmonary bullae * Convulsions * Current history of malignancy * Severe myopia or intraocular lens * Patients on K+(ATP) Channel Openers e.g. Nicorandil, Oral Hypoglycemics, Opioid Analgesics, Catecholamines.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Myocardial Hsp72 protein | Intra-operative (During CABG) |
| Myocardial eNOS protein | Intra-Operative (During CABG) |
| Serum Troponin-T | Peri-operative |
| Serum soluble ICAM-1 | Peri-operative |
| Serum soluble PSGL-1 | Peri-operative |
| Serum soluble P-Selectin | Peri-operative |
| Serum soluble E-Selectin | Peri-operative |
Secondary
| Measure | Time frame |
|---|---|
| Low cardiac output status | Post operative |
| Pulmonary complications | Post operative |
| Renal Complications | Post operative |
| All cardiovascular haemodynamic parameters as measured by a pulmonary artery catheter | Peri-operative |
| Gastrointestinal complications | Post operative |
| Wound complications | Post operative |
| Cost of ICU stay | Post operative |
| Cerebrovascular complications | Post operative |
| Duration of mechanical ventilation | Post Operative |
| Duration of endotracheal intubation | post operative |
| Length of stay in ICU | Post-operative |
| Blood loss | Post operative |
| Inotrope usage | Post operative |
| Atrial Fibrillation | Post operative |
Countries
United Kingdom
Outcome results
None listed